Blood Podcast

Follow Blood Podcast
Share on
Copy link to clipboard

The Blood Podcast will summarize content recently published in Blood the most cited peer-reviewed publication in the field of hematology.

American Society of Hematology


    • Jun 26, 2025 LATEST EPISODE
    • weekdays NEW EPISODES
    • 19m AVG DURATION
    • 327 EPISODES


    Search for episodes from Blood Podcast with a specific topic:

    Latest episodes from Blood Podcast

    An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM

    Play Episode Listen Later Jun 26, 2025 18:24


    In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers report on a machine learning model that identifies 25% of patients with poor outcomes. After that: preventing priapism in men with sickle cell anemia. A recent phase 2 feasibility study shows high rates of recruitment, retention, and adherence to oral therapies, coupled with a significant reduction in the risk of this difficult complication. Finally, new research indicates that hallmarks of terminal T-cell exhaustion are absent in multiple myeloma, from diagnosis through maintenance therapy. We explore these provocative and counterintuitive findings arising from profiling of blood and marrow samples.Featured Articles:Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisA controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafilHallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy

    Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and novel protein biomarkers for risk stratification in a

    Play Episode Listen Later Jun 23, 2025 19:38


    In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

    Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets

    Play Episode Listen Later Jun 19, 2025 41:28


    Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma.See the full review series on high risk lymphoma in volume 144, issue 25 of Blood.

    A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset

    Play Episode Listen Later Jun 12, 2025 20:30


    In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

    Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

    Play Episode Listen Later Jun 10, 2025 9:47


    In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, involving 583 episodes of progression, found that simultaneous confirmation of disease progression using two different markers (e.g., serum protein electrophoresis and serum free light chain assay) was 98% accurate, compared to 82% for sequential confirmation. This suggests that simultaneous confirmation could improve clinical trial accuracy and reduce false censoring. The International Myeloma Working Group is set to revise its response criteria to incorporate these findings, potentially simplifying disease assessment and reducing the need for multiple blood draws.

    How I Treat Series on Geriatric Hematology

    Play Episode Listen Later Jun 5, 2025 17:19


    In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.

    Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance

    Play Episode Listen Later Jun 5, 2025 16:06


    In this week's episode, we'll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences in glycosylation affect the clearance of human plasma-derived and recombinant von Willebrand factor concentrates.Featured Articles:Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcomeCyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentEnhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

    New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE

    Play Episode Listen Later May 29, 2025 19:46


    In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.Featured Articles:One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themVenetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLHisto–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

    How I Treat Transfusion Medicine (part 2)

    Play Episode Listen Later May 22, 2025 33:57


    In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George.Find the full published review series in Volume 145 Issue 20 of Blood Journal.

    Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymph

    Play Episode Listen Later May 22, 2025 20:57


    In this week's episode we'll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.Featured ArticlesClonal Hematopoiesis Landscape in Frequent Blood DonorsIntegrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseUpfront Blinatumomab Improves MRD Clearance and Outcome in Adult Ph-negative B-lineage ALL: The GIMEMA LAL2317 Phase 2 Study

    How I Treat Transfusion Medicine (part 1)

    Play Episode Listen Later May 15, 2025 32:12


    In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RBC antigens. Find the full published review series in Volume 145 Issue 20 of Blood Journal.

    Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT

    Play Episode Listen Later May 15, 2025 18:15


    In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

    Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease

    Play Episode Listen Later May 8, 2025 19:58


    In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

    Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature

    Play Episode Listen Later May 1, 2025 18:12


    In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffuse large B-cell lymphomas into one of five genetic subtypes. It's an inclusive taxonomy that they say provides actionable genetic information in almost all patients with DLBCL. Finally, new insights on NETS, or neutrophil extracellular traps. In the liver vasculature, NET removal leads to secondary inflammation, resulting in new waves of NETS that may impact future infection. We'll review these and other findings from this recent mouse model study.Featured Articles:Decoding functional hematopoietic progenitor cells in the adult human lungDLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphomaDonor regulatory T-cell therapy to prevent graft-versus-host disease

    Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathy

    Play Episode Listen Later Apr 24, 2025 19:06


    In this week's episode we'll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients with sickle cell disease.Featured Articles:PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia 17R-Resolvin D1 Protects Against Sickle Cell Related Inflammatory Cardiomyopathy in Humanized Mice 

    How I Treat Myeloproliferative Neoplasms

    Play Episode Listen Later Apr 17, 2025 38:36


    In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat series in volume 145 issue 16 of Blood.

    The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL

    Play Episode Listen Later Apr 17, 2025 18:49


    In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options. After that: Response to DDAVP, or desmopressin, in bleeding disorders. This study is the first large scale meta-analysis to assess the response rate to DDAVP in bleeding disorders. Authors provide new insights into determinants of response, which vary according to the disease type. Finally, turning to diffuse large B cell lymphoma. Germinal center B cells depend on the activity of DOT1 and EZH2 to maintain their pro-proliferative identity. New research shows that combined treatment with DOT1L and EZH2 inhibitors has synergistic activity in vitro.Featured Articles:Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialDDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysisTargeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma

    Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma

    Play Episode Listen Later Apr 10, 2025 20:59


    In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

    Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL

    Play Episode Listen Later Apr 3, 2025 15:26


    In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.Featured Articles:Aging platelets shift their hemostatic properties to inflammatory functionsOdronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyDissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

    Blood Bonus Episode: What is a Blood group?

    Play Episode Listen Later Mar 31, 2025 14:59


    In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype”, speaks with Blood Associate Editor Dr. Erica Wood about the discovery of the genetic basis for the inherited AnWj-negative blood group phenotype. The discovery that Mal protein is expressed on red blood cell membranes of AnWj-positive, but not AnWj-negative individuals, and that homozygous deletion in MAL causes the AnWj-negative blood group phenotype, helps answer a decades-old mystery related to the high prevalence red blood cell antigen AnWj and forms the basis of a new blood group system. 

    Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait

    Play Episode Listen Later Mar 27, 2025 19:16


    In this week's episode, we'll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles:Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationHow I diagnose and treat acute infection–associated purpura fulminansSickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

    Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis

    Play Episode Listen Later Mar 20, 2025 19:07


    In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

    Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL

    Play Episode Listen Later Mar 13, 2025 21:28


    In this week's episode we'll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.Featured Articles:Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesDevelopment of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaDNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

    Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk

    Play Episode Listen Later Mar 6, 2025 17:48


    In this week's podcast, a potential new therapeutic target in beta-thalassemia. The E3 ubiquitin ligase AMBRA1 promotes autophagic clearance of free alpha-globin. Researchers describe mutations in the AMBRA1 gene that impair this clearance, exacerbating ineffective erythropoiesis and disease severity. After that: targeting MYD88 mutations. Lasalocid-A is a compound that selectively binds to the MYD88 L265P mutant protein, which is found in a range of B-cell lymphomas. New research shows its potential to inhibit tumor growth, overcome ibrutinib resistance, and synergize with venetoclax. Finally: air pollution is linked to an increased risk of venous thromboembolism in a prospective, community-based cohort study. The findings highlight the harms of pollution, and support the case for global efforts to improve public health.Featured Articles:Mutations in AMBRA1 aggravate β-thalassemia by impairing autophagy-mediated clearance of free α-globinLasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutationAir pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis

    Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal antibodies

    Play Episode Listen Later Feb 27, 2025 19:28


    In this week's episode we'll learn more about the significance of hypercalcemia in monoclonal gammopathy of undetermined significance, the role of neutrophil gelatinase-associated lipocalin in hemostasis, and the feasibility of combining CD19-targeted NK- or T-cell therapy with anti-CD19 monoclonal antibodies.Featured Articles:Approaching Hypercalcemia in Gammopathy of Undetermined Significance: Insights from the iStopMM study Deficiency of neutrophil gelatinase-associated lipocalin elicits Hemophilia-like bleeding and clotting disorder Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis 

    Review Series on a Quarter Century of TKIs in CML

    Play Episode Listen Later Feb 27, 2025 33:05


    In this Review Series episode Reflections on a Quarter Century of TKIs in CML introduced by Associate Editor Dr. Jason Gottlieb, we'll hear from contributing authors Drs. Brian Drucker, Francois Guillot, Tim Hughes and Michael Deininger, as they discuss how CML treatment has been impacted since the introduction of tyrosine kinase inhibitors 25 years ago.Click here to view the complete Review Series featured in Volume 145 Issue 9 of Blood.

    A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes

    Play Episode Listen Later Feb 21, 2025 19:09


    In this week's episode, we'll hear about a “belt and suspenders” approach to paroxysmal nocturnal hemoglobinuria, or PNH. We'll review long-term efficacy data for danicopan—an oral complement factor D inhibitor recently approved as an add-on to C5 inhibitor therapy.After that: researchers show how oral pathogens may exacerbate chronic graft-versus-host disease. And they assess targeted interventions to mitigate these effects. Finally, we move from the oral to the gut microbiome. New findings suggest that intestinal dysbiosis, induced by antibiotics, may adversely affect outcomes among patients who are receiving CAR-T cell therapy.Featured Articles:Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVHOral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host diseaseAntibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

    Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

    Play Episode Listen Later Feb 13, 2025 23:14


    In this week's episode we'll find out about longer term results from a pivotal trial of mosunetuzumab in relapsed/refractory follicular lymphoma, potential use of CD70 CAR T-cells that secrete an anti-CD33/anti-CD3 bispecific antibody as a therapy for acute myeloid leukemia, and how ferroptosis regulates hemolysis in stored red blood cells.Featured Articles:Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesCD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLFerroptosis regulates hemolysis in stored murine and human red blood cells

    Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor

    Play Episode Listen Later Feb 13, 2025 31:38


    In this Review Series episode on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor introduced by Dr. Thomas Ortel, we'll hear from contributing authors Drs. Ben Samuelson Jones, Mac Monroe and Peter Lenting as they discuss how the functional roles of these 3 proteins are interconnected. Click here to view the complete Review Series featured in Volume 144 Issue 21 of Blood.

    Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor

    Play Episode Listen Later Feb 6, 2025 18:41


    In this week's episode we'll learn about asciminib plus dasatinib in Philadelphia chromosome-positive acute leukemia. In a phase 1 study, combining two tyrosine kinase inhibitors with distinct mechanisms of action had encouraging activity in patients with de novo disease. After that: new research demonstrates that the iron exporter ferroportin contributes to the iron-sensing properties of liver endothelial cells. But is it the primary mediator of systemic iron homeostasis? Finally: anemia in pregnant patients with beta-thalassemia minor. In the third trimester, about one-third of patients have hemoglobin levels of 9 grams per deciliter or lower. This report may help to guide the appropriate diagnosis of anemia while limiting unnecessary testing and interventions. Featured Articles:Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemiaThe hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in miceβ-Thalassemia minor is associated with high rates of worsening anemia in pregnancy

    First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia

    Play Episode Listen Later Jan 30, 2025 20:37


    In this week's episode we'll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.Featured Articles:Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationDevelopment of hyperdiploidy starts at an early age and takes a decade to completeA phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia

    Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex

    Play Episode Listen Later Jan 23, 2025 19:02


    In this week's episode we'll learn about C3-targeted therapy in autoimmune hemolytic anemias. Based on results of an open-label, phase 2 study, pegcetacoplan was well-tolerated, with encouraging efficacy, particularly in patients with cold agglutinin disease. After that: Venetoclax sensitivity testing to predict AML response. In a significant step toward precision medicine, researchers have validated an assay capable of predicting response to the venetoclax-azacitidine regimen. Finally, an improved basic understanding of human coagulation factor XIII. Investigators present the cryo-electron microscopy structure of Factor XIII complex, providing new insights into etiology and the deleterious effects of certain specific mutations.Featured Articles:Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemiaEx vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trialCryo-EM structure of the human native plasma coagulation factor XIII complex

    Review Series on Globin Disorders

    Play Episode Listen Later Jan 23, 2025 23:17


    In this Review Series episode on Globin Disorders introduced by Drs. Thomas Coates and Irene Roberts, we'll hear from Dr. Douglas Higgs and Dr. Mitchell Weiss as they address advances in our understanding of globin gene biology.Click here to view the complete Review Series featured in Volume 144 Issue 8 of Blood.

    Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell lymphoma

    Play Episode Listen Later Jan 16, 2025 21:35


    In this week's episode we'll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma. Featured Articles:Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaIFN-I promotes T-cell–independent immunity and RBC autoantibodies via modulation of B-1 cell subsets in murine SCDGenetic alteration of class I HLA in cutaneous T-cell lymphoma

    Iron overload aggravates MDS pathophysiology; long-term outcomes after TPO-RA treatment in ITP; new insights into APL treatment outcomes by age and risk

    Play Episode Listen Later Jan 9, 2025 17:20


    In this week's episode we'll learn about the role of iron in myelodysplastic syndromes, or MDS. After that: long-term treatment outcomes in immune thrombocytopenia from the STOPAGO study.  Finally, new insights into APL treatment outcomes and prognostic factors from the large-scale Harmony APL project which used ATRA-Arsenic combination therapy.Featured Articles:Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical studyLong-term follow-up of the STOPAGO studyAcute promyelocytic leukemia: long-term outcomes from the HARMONY project

    Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

    Play Episode Listen Later Jan 2, 2025 20:19


    In this week's episode, we'll learn about the prevalence and impact of dexamethasone dose reductions during triple or quadruple therapy for newly diagnosed multiple myeloma, a conditional knockout mouse model for testing gene therapy in X-linked sideroblastic anemia, and real-world efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.Featured Articles:Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisAn erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSASafety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

    Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

    Play Episode Listen Later Dec 26, 2024 19:01


    In this week's episode, we'll be comparing BTK inhibitors in relapsed/refractory CLL. Then, we'll hear how researchers in the UK unraveled the genetic background of the AnWj blood group.  Finally we'll learn about the role of BCL-2 and BAFF in CLL cell survival following venetoclax therapy. Featured Articles:Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotypeSustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINEVenetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia

    Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

    Play Episode Listen Later Dec 19, 2024 20:05


    In this week's episode, we'll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who receive stem cell transplants, and a cell death process that may help account for increased thromboembolic risk in patients receiving cancer chemotherapy.Featured Articles:Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaEmapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerismGSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential

    Unravelling follicular lymphoma subtypes; stroke rate trends in sickle cell disease; procoagulant platelet activation promotes venous thrombosis

    Play Episode Listen Later Dec 12, 2024 18:38


    In this week's episode, unravelling follicular lymphoma subtypes. Researchers dissect the biological diversity of follicular lymphoma and introduce a new prognostic mode, that could change the way this B-cell neoplasm is subtyped and treated. Then, concerning stroke rate trends in sickle cell disease. A new report shows increasing rates of cerebrovascular events among people with SCD in California. Finally, procoagulant platelet activation promotes venous thrombosis. Investigators report finding procoagulant platelets in the circulation and in thrombi of patients and mice with DVT or PE. Featured Articles:Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significanceRates of strokes in Californians with sickle cell disease in the post-STOP eraProcoagulant platelet activation promotes venous thrombosis

    Clonal hematopoiesis in patients with telomere biology disorders, genomic alterations in extracutaneous juvenile xanthogranulomas, and the BCMA-CD3 bispecific antibody teclistamab in relapsed/refractory multiple myeloma

    Play Episode Listen Later Dec 5, 2024 20:11


    In this week's episode we'll learn more about how clonal hematopoiesis affects prognosis in patients with telomere biology disorders, consider recently uncovered molecular subtypes of extracutaneous juvenile xanthogranulomas, and discuss a clinical trial of the BCMA-CD3 bispecific antibody teclistamab in patients with relapsed/refractory multiple myeloma who have received previous BCMA-targeted therapy.Featured Articles:Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutationsRecurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissueEfficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

    Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH

    Play Episode Listen Later Nov 28, 2024 18:54


    In this week's podcast, we'll learn about targeting mutant calreticulin in MPNs, or myeloproliferative neoplasms. Then, it's time to address bleeding and clotting in cancer. Results of the prospective, observational CAT-BLED study provide much needed data on the high risk of clinically relevant bleeding, and its association with all-cause mortality, among cancer patients receiving systemic therapy. Finally, we'll revisit diagnostic guidelines for familial HLH, or hemophagocytic lymphohistiocytosis. The authors present new and improved diagnostic criteria with revised clinical criteria, and guidelines on cellular and genetic diagnostic assays.Featured Articles:Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPNBleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort studyDiagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited

    Review Series on T-Cell Lymphoma

    Play Episode Listen Later Nov 21, 2024 33:21


    In this Review Series episode on T-Cell Lymphomas introduced by Dr. Philippe Armand we'll hear from Drs. Laurence de Leval, Javeed Iqbal, and Enrica Marchi about their work concerning new treatment practices and insights to various t-cell lymphomas.Click here to view the complete Review Series featured in Volume 144 Issue 18 of Blood.

    Stratifying risk in acute myeloid leukemia, daratumumab plus chemotherapy in relapsed-refractory pediatric leukemias, and a method for creating genetically engineered platelets

    Play Episode Listen Later Nov 21, 2024 17:49


    In this week's episode we'll learn more about a new risk classification scheme for use in patients with acute myeloid leukemia who are ineligible for intensive therapy, efficacy and safety of daratumumab plus chemotherapy in pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, and a blood bank-compatible method for creating genetically engineered platelets with a wide range of potential uses.Featured Articles:Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients with AML Treated With Venetoclax and Azacitidine Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study Genetic Engineering of Transfusable Platelets with mRNA-Lipid Nanoparticles is Compatible with Blood Banking Practices  

    Exploring the ecosystem of extramedullary myeloma; role of ruxolitinib for pediatric acute GvHD; “YAP”-ing about YAP1 and thrombopoiesis in ITP

    Play Episode Listen Later Nov 14, 2024 18:37


    In this week's episode we'll learn about new explorations in extramedullary myeloma. Then, we'll hear about the role of ruxolitinib in children with acute GvHD. Finally: yapping about YAP1 as a new treatment target in immune thrombocytopenia. Featured Articles:Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myelomaRuxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 studyYAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

    First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia

    Play Episode Listen Later Nov 7, 2024 21:19


    In this week's episode we'll learn more about the ASCEND study, which investigated first-line asciminib in chronic phase chronic myeloid leukemia; a new risk score for myeloid neoplasm transformation in patients with clonal cytopenia of undetermined significance; and use of RHD genotyped D-positive blood transfusions in patients with sickle cell and unexpected anti-D antibodies.Featured ArticlesAsciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia - Results from the ASCEND StudyRisk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence Genotyped RhD+ red cells for D-positive patients with sickle cell disease with conventional RHD and unexpected anti-D 

    Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML

    Play Episode Listen Later Oct 31, 2024 19:03


    In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab in previously untreated CLL. Then, we'll hear about dual epi-immunotherapy in classical Hodgkin lymphoma. Finally we'll explore redefining risk of treatment failure in CML.Featured Articles:Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyEpigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphomaA predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

    Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis

    Play Episode Listen Later Oct 24, 2024 20:32


    In this week's episode we'll learn more about the role of ERG loss-of-function variants in bone marrow failure and hematological malignancies, a proposed pathway linking factor 11 activation to increased vascular permeability during inflammation, and new clinical criteria for diagnosing anemia, defining transfusion-dependence, and evaluating anemia treatment responses in patients with myelofibrosis.Featured Articles:Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predispositionCoagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivoProposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

    Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia

    Play Episode Listen Later Oct 17, 2024 18:59


    In this week's episode, we'll learn about the role of a platelet-specific glycoprotein receptor in abdominal aortic aneurysm formation, the influence of TP53 mutations on outcomes for patients with 5q-deleted myelodysplastic syndrome, and a rational combination treatment intended to produce more durable responses in patients with refractory B-cell acute lymphoblastic leukemia who are treated with CAR T-cell therapy.Featured Articles:Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic targetInfluence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionA phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

    Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS

    Play Episode Listen Later Oct 10, 2024 21:48


    In this week's episode we'll learn about refining risk stratification in T-cell acute lymphoblastic leukemia, or ALL. After that, we'll discuss a novel gene therapy approach in severe alpha-thalassemia. Investigators describe an innovative mouse model and an effective gene therapy approach, renewing prospects for the development of novel strategies to treat this disease. Finally, we'll hear about how genomic profiling has helped identify subgroups associated with distinct clinical phenotypes and outcomes in the molecular taxonomy of myelodysplastic syndromes, or MDS. Featured Articles NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup ofpatientsUse of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviralgene therapyMolecular taxonomy of myelodysplastic syndromes and its clinical implications

    A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT

    Play Episode Listen Later Oct 3, 2024 18:30


    In this week's episode we'll discuss a novel tripartite fusion drives treatment resistance in acute promyelocytic leukemia. In some patients with atypical APL, these novel retinoic acid receptor gene fusions result in truncation of the ligand binding domain of the retinoic acid receptor protein, resulting in non-responsiveness to treatment with all-trans retinoic acid. After that: managing immune thrombotic thrombocytopenia or iTTP without therapeutic plasma exchange, or TPE. Finally, hope for motherhood after allogeneic HCT.Featured Articles: Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APLManagement of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchangeHope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

    Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis

    Play Episode Listen Later Sep 26, 2024 23:17


    In this week's episode we'll discuss the safety and efficacy of pirtobrutinib with or without rituximab in relapsed/refractory CLL; learn more about erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine; and discuss how targeting PKC alpha alleviates iron overload in diabetes and hemochromatosis through the inhibition of ferroportin.Featured Articles:Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: Phase 1b BRUIN trialMurine models of erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxineTargeting PKCα alleviates iron overload in diabetes and hemochromatosis through the inhibition of ferroportin

    Claim Blood Podcast

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel